Wim A. van der Steeg, M.D.; Christopher P. Cannon, M.D., F.A.C.C. As extensively discussed in literature, this unexpected outcome is hypothesized to relate to the ...

New research has found that women who have had both ovaries surgically removed before the age of 50 and carry a variant of the apolipoprotein gene, the APOE4 allele, are at high risk of late-life ...

As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have ...

Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...

New research published by a team of researchers from the University of Toronto in collaboration with colleagues from the ...

Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), ...

TORONTO: Women who have had both ovaries surgically removed before age 50, and carry a variant of the apolipoprotein gene, ...

The researchers found that muvalaplin resulted in placebo-adjusted reductions of 47.6, 81.7, and 85.8 percent in ...

Women who have had both ovaries surgically removed before age 50, and carry a variant of the apolipoprotein gene, are at a ...

Forty-four patients had genetically confirmed FCS and 31 patients had clinically diagnosed FCS. Plozasiran, at the 25 mg dose being proposed for marketing approval, induced rapid, deep, and sustained ...